Protagonist Therapeutics (PTGX) Interest Expenses (2020)

Protagonist Therapeutics has reported Interest Expenses for 11 years, with the latest figure at $501.3 million in Q4 2025.

• Quarterly Interest Expenses rose 59507.61% year-over-year to $501.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $501.3 million (up 85886.28% YoY) and the FY2025 annual result came in at $501.3 million, up 227.86% from the prior year.
• Interest Expenses climbed to $501.3 million in Q4 2025 per PTGX's latest filing, from $841000.0 in the prior quarter.
• Over five years, Interest Expenses peaked at $501.3 million in Q4 2025 and troughed at -$1.6 million in Q4 2023.
• A 5-year average of $57.5 million and a median of $2.1 million in 2024 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2021 and 2025: Interest Expenses slumped 1039.37% in 2021, then surged 59507.61% in 2025.
• Over 5 years, Interest Expenses stood at -$1.2 million in 2021, then jumped by 156.58% to $675000.0 in 2022, then plunged by 344.0% to -$1.6 million in 2023, then soared by 151.06% to $841000.0 in 2024, then soared by 59507.61% to $501.3 million in 2025.
• According to Business Quant data, Interest Expenses over the past three periods registered $501.3 million, $841000.0, and $1.9 million for Q4 2025, Q4 2024, and Q3 2024 respectively.